Lab Automation in Genomics Market Report 2026

The lab automation in genomics market size has grown rapidly in recent years. It will grow from $2.68 billion in 2025 to $3.09 billion in 2026 at a compound annual growth rate (CAGR) of 15.5%. The growth in the historic period can be attributed to growing volume of genomic research activities, increasing complexity of genomic workflows, need to reduce manual laboratory errors, rising adoption of next-generation sequencing, expansion of biotech and pharmaceutical research.

The lab automation in genomics market size is expected to see rapid growth in the next few years. It will grow to $5.05 billion in 2030 at a compound annual growth rate (CAGR) of 13%. The growth in the forecast period can be attributed to increasing demand for precision medicine, rising investments in genomics infrastructure, growing adoption of ai-enabled lab automation, expansion of genomics-based clinical diagnostics, increasing focus on laboratory efficiency and cost reduction. Major trends in the forecast period include increasing adoption of fully automated genomic workflows, rising demand for high-throughput sample processing, growing integration of robotics in genomics laboratories, expansion of modular and scalable automation systems, improved reproducibility and standardization in genomic testing.

The increasing adoption of precision medicine is anticipated to drive the growth of lab automation in the genomics market moving forward. Precision medicine is a tailored approach to healthcare that accounts for individual variations in genes, environment, and lifestyle to provide personalized medical treatments. The demand for precision medicine is rising due to multiple factors, including advancements in genomics, targeted therapies, patient-focused care, and drug development. Precision medicine requires extensive genetic testing to identify disease-related genes, prompting laboratories to process large volumes of samples quickly and accurately, which encourages the use of automated systems. For example, in February 2024, according to the Personalized Medicine Coalition, a US-based non-profit organization, the FDA approved 16 new personalized therapies for patients with rare diseases in 2023, compared to six in 2022. Thus, the increasing adoption of precision medicine is fueling the growth of lab automation in the genomics market.

Major companies operating in lab automation within the genomics market are concentrating on developing advanced solutions such as automated whole genome sequencing (WGS) to drive progress in genomics research, clinical diagnostics, and personalized medicine. Automated whole genome sequencing (WGS) involves sequencing an individual’s genome using high-throughput, automated sequencing technologies. For example, in May 2023, Clear Labs, Inc., a US-based genomics testing company, introduced Clear Dx. This new solution offers fully automated sample processing, ensuring accurate and consistent library preparation and management for genomics. Clear Dx automation minimizes human variability and delivers consistency throughout sequencing, resulting in reliable and reproducible outcomes. It simplifies genome sequencing, reducing hands-on time to just 30 minutes with a single touch point, making whole genome sequencing accessible even without prior training.

In March 2023, INTEGRA Biosciences AG, a Switzerland-based provider of laboratory instruments and automated solutions for liquid handling, media preparation, and cell cultivation, acquired Miroculus, Inc. for an undisclosed amount. Through this acquisition, INTEGRA Biosciences AG obtains access to Miroculus, Inc.’s proprietary digital microfluidics technology for automating next-generation sequencing (NGS) sample preparation, enhancing its genomics automation capabilities and expanding its presence in advanced sequencing workflows. Miroculus, Inc. is a US-based biotechnology company focused on digital microfluidics-powered automation for complex genomics protocols, recognized for its Miro Canvas platform that simplifies and streamlines NGS library preparation.

Major companies operating in the lab automation in genomics market are Thermo Fisher Scientific Inc., Tecan Group Ltd., Hamilton Company, Agilent Technologies Inc., PerkinElmer Inc., Danaher Corporation, Becton Dickinson and Company, Bio-Rad Laboratories Inc., QIAGEN N.V., Illumina Inc., Gilson Incorporated, Fluidigm Corporation, Beckman Coulter Life Sciences, Analytik Jena AG, LGC Biosearch Technologies, Eppendorf AG, Roche Diagnostics, Hudson Robotics, Andrew Alliance, Automata Technologies.

North America was the largest region in the lab automation in genomics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the lab automation in genomics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the lab automation in genomics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have moderately impacted the lab automation in genomics market by increasing the cost of imported robotic systems, automated liquid handlers, and specialized electronic components. Equipment segments such as robotic arms, automated storage systems, and liquid handling platforms are most affected, particularly in North America and Europe due to dependence on global manufacturing supply chains. Hospitals, biotech companies, and research institutes face higher capital expenditure for automation upgrades. However, tariffs have also encouraged local manufacturing, supplier diversification, and long-term strengthening of regional automation and life sciences equipment ecosystems.

The lab automation in genomics market research report is one of a series of new reports that provides lab automation in genomics market statistics, including lab automation in genomics industry global market size, regional shares, competitors with a lab automation in genomics market share, detailed lab automation in genomics market segments, market trends and opportunities, and any further data you may need to thrive in the lab automation in genomics industry. This lab automation in genomics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Lab automation in genomics involves the use of advanced technologies and systems to optimize and automate various laboratory processes related to genomic research and analysis. The purpose of lab automation in genomics is to enhance the efficiency, accuracy, and reproducibility of genomic studies by minimizing manual errors, increasing throughput, and speeding up data analysis.

The primary types of lab automation in genomics include automated liquid handlers, automated plate handlers, robotic arms, automated storage and retrieval systems, and others. Automated liquid handlers are laboratory instruments designed to accurately dispense specific volumes of liquids automatically, simplifying tasks such as sample preparation and assay setup. These instruments improve efficiency and precision in genomic workflows. They operate through several systems, including continuous automation systems and modular automation systems, for a variety of applications, including hospitals and private laboratories, biotech and pharmaceutical companies, academic and research institutions, and more.

The lab automation in genomics market consists of revenues earned by entities by providing services such as sample preparation, sequencing library preparation, data analysis, sample tracking and management, quality control, customization, and integration. The market value includes the value of related goods sold by the service provider or included within the service offering. The lab automation in genomics market also includes sales of centrifuges, thermal cyclers, sequencing platforms, PCR automation systems, and robotic workstations. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.